WINT
Windtree Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -31.1%
- EPS
- +99.1%
- Free cash flow
- +1.1%
- Operating cash flow
- +1.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +92.7%
- EBIT
- -42.6%
- Net income
- +73.0%
- EPS
- +97.8%
- Free cash flow
- -14.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025